The significance of postoperative follow-up of patients with advanced colorectal cancer using circulating tumor DNA—Selected case studies

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F16%3AN0000300" target="_blank" >RIV/00064190:_____/16:N0000300 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1158/1538-7445.CRC16-B24" target="_blank" >http://dx.doi.org/10.1158/1538-7445.CRC16-B24</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1158/1538-7445.CRC16-B24" target="_blank" >10.1158/1538-7445.CRC16-B24</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The significance of postoperative follow-up of patients with advanced colorectal cancer using circulating tumor DNA—Selected case studies

Popis výsledku v původním jazyce

AACR Special Conference: Colorectal Cancer: From Initiation to Outcomes; September 17-20, 2016; Tampa, FL Introduction: One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term postoperative follow-up. Sometimes referred to as a “liquid (re)biopsy” it can be performed frequently at relatively short intervals (months or even weeks) with minimal invasivity. The presence of the disease and the actual extent of the tumor burden (tumor mass) within the patient body can be monitored. This is of particular importance especially when evaluating radicality of surgical tratment, monitoring the response to systemic anticancer therapy as well as for early detection of disease progression or recurrence. In this presentation we demonstrate clinical utility of ctDNA detection in a postoperative follow-up setting on several cases of mCRC patients. Patient cohort: A total of 91 patients undergoing resection of liver metastases were enrolled into the multicentre study involving three surgical centers. In addition to the baseline ctDNA testing a longitudinal observation was conducted for 16 patients by evaluating ctDNA presence (i) prior to surgery, (ii) a week after surgery and (iii) at subsequent intervals over the next several months after the surgery. The presence and the levels of ctDNA were correlated with radicality of surgical treatment and the actual clinical status of the patient. Five separate cases of patients who were followed for over a year by means of ctDNA monitoring are presented. Results: The R0 (curative) resection correlated with postoperative ctDNA negativity in 4 out of 5 cases of surgical procedures (80%). One of the patients with R0 surgeries, a radio-frequency ablation (RFA) of small liver metastases, continued displaying ctDNA and, subsequently, was diagnosed with the disease recurrence within the scar 3 months after the surgery. A post-surgical ctDNA positivity correlated with one case of R1 (residual tumor) resection. Four patients did show a postoperative relapse of the disease, which was documented in 3 of the cases by increasing levels of ctDNA even as the imaging examination result was negative. In one patient showing remission with no recurrence of tumor the ctDNA remained steadily negative during the entire follow-up period. Conclusion: CtDNA detection in patients with metastatic CRC is a viable tool for long-term follow-up and early detection of disease recurrence as well as in confirmation of the radicality of surgical treatment. The approach exhibits high specificity and at the minimal invasivity low burden to the patient.

Název v anglickém jazyce

The significance of postoperative follow-up of patients with advanced colorectal cancer using circulating tumor DNA—Selected case studies

Popis výsledku anglicky

AACR Special Conference: Colorectal Cancer: From Initiation to Outcomes; September 17-20, 2016; Tampa, FL Introduction: One of the most notable applications for circulating tumor DNA (ctDNA) detection in peripheral blood of patients with metastatic colorectal cancer (mCRC) is a long-term postoperative follow-up. Sometimes referred to as a “liquid (re)biopsy” it can be performed frequently at relatively short intervals (months or even weeks) with minimal invasivity. The presence of the disease and the actual extent of the tumor burden (tumor mass) within the patient body can be monitored. This is of particular importance especially when evaluating radicality of surgical tratment, monitoring the response to systemic anticancer therapy as well as for early detection of disease progression or recurrence. In this presentation we demonstrate clinical utility of ctDNA detection in a postoperative follow-up setting on several cases of mCRC patients. Patient cohort: A total of 91 patients undergoing resection of liver metastases were enrolled into the multicentre study involving three surgical centers. In addition to the baseline ctDNA testing a longitudinal observation was conducted for 16 patients by evaluating ctDNA presence (i) prior to surgery, (ii) a week after surgery and (iii) at subsequent intervals over the next several months after the surgery. The presence and the levels of ctDNA were correlated with radicality of surgical treatment and the actual clinical status of the patient. Five separate cases of patients who were followed for over a year by means of ctDNA monitoring are presented. Results: The R0 (curative) resection correlated with postoperative ctDNA negativity in 4 out of 5 cases of surgical procedures (80%). One of the patients with R0 surgeries, a radio-frequency ablation (RFA) of small liver metastases, continued displaying ctDNA and, subsequently, was diagnosed with the disease recurrence within the scar 3 months after the surgery. A post-surgical ctDNA positivity correlated with one case of R1 (residual tumor) resection. Four patients did show a postoperative relapse of the disease, which was documented in 3 of the cases by increasing levels of ctDNA even as the imaging examination result was negative. In one patient showing remission with no recurrence of tumor the ctDNA remained steadily negative during the entire follow-up period. Conclusion: CtDNA detection in patients with metastatic CRC is a viable tool for long-term follow-up and early detection of disease recurrence as well as in confirmation of the radicality of surgical treatment. The approach exhibits high specificity and at the minimal invasivity low burden to the patient.

Druh

D - Stať ve sborníku

CEP obor

—

OECD FORD obor

30101 - Human genetics

Projekt

<a href="/cs/project/NV15-27939A" target="_blank" >NV15-27939A: Přínos nové technologie „liquid biopsy“ pro monitoraci komplexní léčby kolorektálního karcinomu ve 3.- 4. stádiu onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název statě ve sborníku

Proceedings of the AACR Special Conference on Colorectal Cancer: From Initiation to Outcomes

ISBN

—

ISSN

0008-5472

e-ISSN

—

Počet stran výsledku

2

Strana od-do

Abstract B24

Název nakladatele

American Association for Cancer Research

Místo vydání

—

Místo konání akce

Talpa, USA

Datum konání akce

17. 8. 2016

Typ akce podle státní příslušnosti

WRD - Celosvětová akce

Kód UT WoS článku

—